EGFR Inhibitors May Help Patients With Treatment-Resistant NF1-Mutant Melanoma
Source: docwirenews, June 2025
Researchers have found that melanomas with neurofibromin 1 (NF1) mutations, which often do not respond to immunotherapy, exhibit increased expression of the epidermal growth factor receptor (EGFR) and may be responsive to treatment with existing EGFR inhibitors. The findings were published in Cancer Research.
When cutaneous melanoma is classified based on genetic driver mutations, up to 27% of patients have mutations in the NF1 gene. While targeted therapies and immune checkpoint inhibitors have improved survival for patients with other genetic subtypes of melanoma, options for those with NF1-mutant melanoma remain limited.
You must be logged in to post a comment.